Get to know our clinical trials
Clinical trial to evaluate LNP023 (iptacopan) in patients with active ANCA-associated vasculitis
THE PURPOSE OF THE STUDY IS TO DETERMINE WHETHER IPTACOPAN IS SAFE AND HAS THE DESIRED EFFECT IN PATIENTS WITH ACTIVE GPA AND PAM (TWO TYPES OF VAA).
Status
In recruitment
headquarters
Pamplona
Early phase
Technical Summary
- A RANDOMIZED CONTROLLED TRIAL TO EVALUATE LNP023 (IPTACOPAN) IN PATIENTS WITH ACTIVE ANCA-ASSOCIATED VASCULITIS
- Code EudraCT: 2023-51052515-00
- Protocol number: CLNP023R12201
- Promoter: Novartis Farmaceutica
- Molecule/Drug: LNP023 (iptacopan)
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.